Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert J Fox

Showing results (21-30 of 256) with videos related to

Pageof 26
Sort By:
Neurology|September 10, 2021
Relationship Between Serum Neurofilament Light and Multiple Sclerosis Disability Progression: Clear as MudCarolyn Goldschmidt, Robert J Fox
Drugs|May 13, 2026
Bruton's Tyrosine Kinase Inhibitors in Multiple SclerosisJeffrey Lambe, Robert J Fox
Current Treatment Options in Neurology|April 21, 2007
Current treatment options in multiple sclerosisAdrienne Boissy, Robert J Fox
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 16, 2021
DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - CommentaryRobert J Fox, Mar Tintore
Continuum (Minneapolis, Minn.)|August 7, 2013
Multiple sclerosis treatment: risk mitigationDaniel Ontaneda, Robert J Fox
The International Journal of Neuroscience|October 12, 2013
Is neuromyelitis optica with advanced age of onset a paraneoplastic disorder?Daniel Ontaneda, Robert J Fox
Neurology|March 26, 2008
Is natalizumab overshooting its rebound?Robert J Fox, Ludwig Kappos
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 5, 2016
Imaging as an Outcome Measure in Multiple SclerosisDaniel Ontaneda, Robert J Fox
The New England Journal of Medicine|April 26, 2013
Oral BG-12 in multiple sclerosisRobert J Fox, Eva Havrdova
Drugs of Today (Barcelona, Spain : 1998)|January 18, 2003
Pathological mechanisms and disease progression of multiple sclerosis: therapeutic implicationsCarl Bjartmar, Robert J Fox
Pageof 26

Showing results (21-30 of 256) with videos related to

Sort By:
Pageof 26
Neurology|September 10, 2021
Relationship Between Serum Neurofilament Light and Multiple Sclerosis Disability Progression: Clear as MudCarolyn Goldschmidt, Robert J Fox
Drugs|May 13, 2026
Bruton's Tyrosine Kinase Inhibitors in Multiple SclerosisJeffrey Lambe, Robert J Fox
Current Treatment Options in Neurology|April 21, 2007
Current treatment options in multiple sclerosisAdrienne Boissy, Robert J Fox
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 16, 2021
DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - CommentaryRobert J Fox, Mar Tintore
Continuum (Minneapolis, Minn.)|August 7, 2013
Multiple sclerosis treatment: risk mitigationDaniel Ontaneda, Robert J Fox
The International Journal of Neuroscience|October 12, 2013
Is neuromyelitis optica with advanced age of onset a paraneoplastic disorder?Daniel Ontaneda, Robert J Fox
Neurology|March 26, 2008
Is natalizumab overshooting its rebound?Robert J Fox, Ludwig Kappos
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 5, 2016
Imaging as an Outcome Measure in Multiple SclerosisDaniel Ontaneda, Robert J Fox
The New England Journal of Medicine|April 26, 2013
Oral BG-12 in multiple sclerosisRobert J Fox, Eva Havrdova
Drugs of Today (Barcelona, Spain : 1998)|January 18, 2003
Pathological mechanisms and disease progression of multiple sclerosis: therapeutic implicationsCarl Bjartmar, Robert J Fox
Pageof 26